Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly

Could weight loss drugs fix UK’s unemployment problem?

US pharmaceuticals group Eli Lilly is to conduct trials of its weight-loss drugs in the UK.

Al Jazeera

Eli Lilly CEO's explains how failing fast leads to success

For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.

Fortune

Eli Lilly Stock: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market and its peers this year, and Wall Street analysts are bullish about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Barchart

Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data and earnings reports from “Magnificent Seven” companies Microsoft and Meta.

Barchart

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama is shedding light on the pharmaceuticals industry behind them

Evening Standard

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Sues Over Knock-Off Weight-Loss Drugs

Eli Lilly has filed three new separate lawsuits accusing vendors and a medical spa of selling knock-off versions of their drug, Zepbound.

International Business Times

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

StockNews.com

UK regulator approves second Alzheimer's drug in months but government won't pay for it

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers

The Independent UK

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money

Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs

The Independent UK

UK's weight loss jab Mounjaro might help people get back to work: All about it

The UK government has announced a novel initiative trial to offer weight loss medication Mounjaro to people with obesity who are unemployed, to improve their health and help them re-enter the workforce, said British Health Minister Wes Streeting said on Tuesday. The trial is part of a broader NHS strategy…

The Times of India

3 Healthcare Stocks That Can Thrive in Any Economy

The healthcare market shows promise due to heightened demand for quality care, technological advancements, preventive measures, and increased public investment, ensuring resilience in any economic condition. Therefore, investors could now consider top healthcare stocks, such as Eli Lilly (LLY), Merck & Co. (MRK), and Abbott Laboratories (ABT). Keep reading.

StockNews.com

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

The Conversation

Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to proposals made by the National Institute for Health and Care Excellence (Nice). Previously, it was only available on the NHS for patients with diabetes.

Barchart

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

StockNews.com

3 Healthcare Stocks to Watch as the Aging Population Drives Demand

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding healthcare giants like Eli Lilly and Company (LLY), UnitedHealth Group (UNH), and Merck & Co. (MRK) to their watchlist. Read…

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

With a robust performance, strategic expansions, and strong analyst endorsements, Eli Lilly appears poised for continued growth, making it a compelling investment opportunity.

Roll Call

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Barchart

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

International Business Times

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

Medical Daily

Eli Lilly's Eczema Drug Gets FDA Approval, Injectable Treatment Available Within Weeks

The new injectable drug, Lebrikizumab, branded as Ebglyss, is approved for treating atopic dermatitis in adults and children aged 12 and older who weigh at least 88 pounds.

The Conversation

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

International Business Times

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.

1 … 17 18 19 20

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations